{"version":"1.0","provider_name":"De Belgische Vereniging voor de Studie van Obesitas","provider_url":"https:\/\/belgium.easo.org\/nl","author_name":"BASO","author_url":"https:\/\/belgium.easo.org\/nl\/author\/chris101\/","title":"Position statement Recommendations Ozempic - The Belgian Association for the Study of Obesity","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"twLBW8d0nE\"><a href=\"https:\/\/belgium.easo.org\/nl\/position-statement-recommendations-ozempic\/\">Positieverklaring Aanbevelingen Ozempic<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/belgium.easo.org\/nl\/position-statement-recommendations-ozempic\/embed\/#?secret=twLBW8d0nE\" width=\"600\" height=\"338\" title=\"\u201cStandpunt Aanbevelingen Ozempic\u201d - De Belgische Vereniging voor de Studie van Obesitas\" data-secret=\"twLBW8d0nE\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/belgium.easo.org\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>","thumbnail_url":"https:\/\/belgium.easo.org\/wp-content\/uploads\/2023\/03\/BASO_New_Logo.png","thumbnail_width":1039,"thumbnail_height":366,"description":"[et_pb_section admin_label=&#8221;section&#8221;] [et_pb_row admin_label=&#8221;row&#8221;] [et_pb_column type=&#8221;4_4&#8243;][et_pb_text admin_label=&#8221;Text&#8221;] In response to recent discussions concerning the use of Ozempic (semaglutide) for the treatment of obesity, the Belgian Association for the Study of Obesity would like to articulate its position on the matter. Attached, you will find our comprehensive response that elaborates on this subject. Our stance is [&hellip;]"}